Biocon eyes Rs 100 cr from psoriasis drug in next four years
PTI: New Delhi, Jan 25 2013, 14:20 IST
It is done for the cause of public health.
Last year, the government had invoked compulsory license to allow Hyderabad-based Natco Pharma to manufacture and sell cancer-treatment drug Nexavar at a price, over 30 times lower than charged by its patent-holder Bayer Corporation.
Previous Story Good sales, low base push Maruti Suzuki India Q3 net profit up two-fold Next Story US foreign policy more than troops and drones: John Kerry
Reader's Comments| Post a Comment
Be the first to comment.
